A reasonable Response to Diphensiprone in Pediatric Alopecia Patient: A Case Report
Alopecia areata (AA) is an autoimmune disorder which accounts for the most frequent cause of inflammation based hair loss among dermatological outpatient attendances. It has an unpredictable course and its etiology has not yet been fully elucidated. Many alternatives treatments are available; however, none of them have been curative or preventive so far. Its treatment must be individualized, and aims at suppressing the phase of activity of the disease. Alopecia areata (AA) persistent for a minimum of 6 months and resistant to other treatments and/or severe AA are indications to use diphencyprone (DPCP). We report a 9 year-old boy with diffuse alopecia areata, who underwent topical immunotherapy with diphencyprone. The application procedures, the results obtained and the clinical follow-up are described. Treatment alternatives should be tried, especially in the pediatric age group, due to the prominent effects of the disease on the patient’s quality of life and consequent development of psychological impairments. In this case; DPCP application is a preferable treatment option in AA in the pediatric age group because is very easy, effective and with less side effects